NCT05945121 Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
| NCT ID | NCT05945121 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan Rogel Cancer Center |
| Condition | Hematopoietic Stem Cell Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-08-25 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2023-08-25 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.
Eligibility Criteria
Inclusion Criteria: * Adult 18 years or older * Referred for HSCT evaluation * Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes) * Able to ambulate unassisted * Ability to understand and the willingness to sign a written informed consent * Ability to use Polar Flow heart rate application Exclusion Criteria: * Severe anemia (hemoglobin \<7 gm/dl) * Untreated high-risk coronary artery disease (left main, triple vessel disease) * Severe aortic stenosis * Recent fracture as assessed via self-report * Gross balance deficits * Severe pain with basic movement * Unable to ambulate unassisted or exercise * NYHA class IV heart failure * Adults unable to give consent, pregnant women, and prisoners are excluded from this study.
Contact & Investigator
Salim Hayek
PRINCIPAL INVESTIGATOR
University of Michigan Rogel Cancer Center
Frequently Asked Questions
Who can join the NCT05945121 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic Stem Cell Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05945121 currently recruiting?
Yes, NCT05945121 is actively recruiting participants. Contact the research team at CancerAnswerLine@med.umich.edu for enrollment information.
Where is the NCT05945121 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT05945121 clinical trial?
NCT05945121 is sponsored by University of Michigan Rogel Cancer Center. The principal investigator is Salim Hayek at University of Michigan Rogel Cancer Center. The trial plans to enroll 10 participants.